This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race Oncology 2019 Annual General Meeting Presentation
https://youtube.com/watch?v=camFwooKzNw
Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene.
• Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00)
• Race’s 5 Path Strategy | Dr Daniel Tillett CSO (10.00 – 39.00)
• Conclusion | Mr Peter Molloy CEO/MD (39.01 – 45.23)
Videography and editing by Sirius Productions